Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

13 Sep 2011
Study sheds new light on how surgery impacts chronic kidney disease, bone health

Study sheds new light on how surgery impacts chronic kidney disease, bone health

5 Aug 2011
Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

3 Aug 2011
Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

Novartis Afinitor Phase III trial on tuberous sclerosis meets primary endpoint

8 Jul 2011
Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

Threshold commences combination Phase 1/2 trial of TH-302 and sunitinib for RCC, GIST and PNET

29 Jun 2011
FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

28 Jun 2011
immatics initiates IMA901 Phase III trial in renal cell carcinoma

immatics initiates IMA901 Phase III trial in renal cell carcinoma

15 Jun 2011
Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

9 Jun 2011
Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

7 Jun 2011
New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

6 Jun 2011
Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

2 Jun 2011
AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

2 Jun 2011
Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

Lymphocyte count serves as simple and effective prognostic indicator in renal cell carcinoma

2 Jun 2011
EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

EMA accepts Pfizer's filing of axitinib for regulatory review to treat advanced renal cell carcinoma

1 Jun 2011
Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

1 Jun 2011
FDA approves SUTENT for treatment of pancreatic NET

FDA approves SUTENT for treatment of pancreatic NET

21 May 2011
Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

21 May 2011
FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

21 May 2011
Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

19 May 2011
Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

19 May 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback